An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy
暂无分享,去创建一个
Vijay Patil | Atanu Bhattacharjee | Amit Joshi | Vanita Noronha | Kumar Prabhash | A. Bhattacharjee | K. Prabhash | V. Noronha | V. Patil | A. Joshi
[1] L. Saltz. Progress in cancer care: the hope, the hype, and the gap between reality and perception. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Fusenig,et al. Tumour angiogenesis : basic mechanisms and cancer therapy , 2008 .
[3] Georgia Salanti,et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. , 2007, The Lancet. Oncology.
[4] A. Bhattacharjee,et al. Time-Dependent Area Under the ROC Curve for Optimum Biological Dose Detection Optimum Biyolojik Doz Tespiti için ROC Eğrisi Altinda Zamana Bağli Alan , 2016 .
[5] Pan Pantziarka,et al. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai , 2016, Ecancermedicalscience.
[6] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[7] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[8] Edward Chu,et al. A history of cancer chemotherapy. , 2008, Cancer research.
[9] D. Ribatti,et al. HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 2016 .
[10] O. Scharovsky,et al. Metronomic chemotherapy: changing the paradigm that more is better , 2009, Current oncology.
[11] R. Maiti. Metronomic chemotherapy , 2014, Journal of pharmacology & pharmacotherapeutics.
[12] L. Goldstein,et al. Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial , 2006 .
[13] D. Ribatti,et al. Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .
[14] R. Kerbel,et al. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] A. Bhattacharjee. Multiple Imputations for Determining an Optimum Biological Dose of a Metronomic Chemotherapy , 2017 .
[16] J. Denekamp,et al. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.
[17] U. Dafni,et al. Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer , 2009, Clinical Cancer Research.
[18] S. Arya,et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. , 2015, Oral oncology.
[19] H. H. Lloyd,et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. , 1970, Cancer chemotherapy reports.
[20] C. Marquette,et al. Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer , 2014, British Journal of Cancer.
[21] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[22] Alternative of clinical end point selection for metronomic studies , 2017 .